WO2000006190A1 - THYMOSIN β4 PROMOTES WOUND REPAIR - Google Patents
THYMOSIN β4 PROMOTES WOUND REPAIR Download PDFInfo
- Publication number
- WO2000006190A1 WO2000006190A1 PCT/US1999/017282 US9917282W WO0006190A1 WO 2000006190 A1 WO2000006190 A1 WO 2000006190A1 US 9917282 W US9917282 W US 9917282W WO 0006190 A1 WO0006190 A1 WO 0006190A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thymosin
- wound healing
- wound
- agent
- tissue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/18—Thymus derived hormone or factor; related peptides
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA01001041A MXPA01001041A (en) | 1998-07-30 | 1999-07-29 | THYMOSIN beta4 PROMOTES WOUND REPAIR. |
AU52443/99A AU766826B2 (en) | 1998-07-30 | 1999-07-29 | Thymosin beta4 promotes wound repair |
EP99937654A EP1100529B2 (en) | 1998-07-30 | 1999-07-29 | Thymosin beta 4 promotes wound repair |
CA002338928A CA2338928A1 (en) | 1998-07-30 | 1999-07-29 | Thymosin .beta.4 promotes wound repair |
DE69924615T DE69924615T3 (en) | 1998-07-30 | 1999-07-29 | THYMOSINE BETA 4 STIMULATED WOUND HEALING |
AT99937654T ATE292473T1 (en) | 1998-07-30 | 1999-07-29 | THYMOSIN BETA 4 STIMULATES WOUND HEALING |
DK99937654.4T DK1100529T4 (en) | 1998-07-30 | 1999-07-29 | Thymosin beta 4 promotes wound healing |
US09/772,445 US20070111931A9 (en) | 1998-07-30 | 2001-01-29 | Compositions and methods for promoting wound healing and tissue repair |
HK01108257A HK1038307A1 (en) | 1998-07-30 | 2001-11-23 | Thymosin beta 4 promotes wound repair. |
US10/714,405 US20040170625A1 (en) | 1998-07-30 | 2003-11-17 | Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivatives |
US10/853,505 US7268118B2 (en) | 1998-07-30 | 2004-05-26 | Thymosin β4 compositions |
US11/284,430 US8143218B2 (en) | 1998-07-30 | 2005-11-22 | Treatment of skin, and wound repair, with thymosin beta 4 |
US11/284,408 US20070015698A1 (en) | 1998-07-30 | 2005-11-22 | Treatment of skin, and wound repair, with thymosin beta 4 |
US11/649,889 US20070191275A1 (en) | 1998-07-30 | 2007-01-05 | Method of treating, preventing, inhibiting or reducing damage to cardiac tissue with thymosin beta 4 fragments |
US11/715,997 US20090023663A1 (en) | 1998-07-30 | 2007-03-09 | Thymosin beta 4 compositions and methods |
US11/841,575 US20080096817A1 (en) | 1998-07-30 | 2007-08-20 | METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES |
US12/775,959 US20110020449A1 (en) | 1998-07-30 | 2010-05-07 | Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives |
US15/594,045 US20170326207A1 (en) | 1998-07-30 | 2017-05-12 | Thymosin Beta 4 Promotes Wound Repair |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9469098P | 1998-07-30 | 1998-07-30 | |
US60/094,690 | 1998-07-30 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/772,445 Continuation US20070111931A9 (en) | 1998-07-30 | 2001-01-29 | Compositions and methods for promoting wound healing and tissue repair |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000006190A1 true WO2000006190A1 (en) | 2000-02-10 |
Family
ID=22246605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/017282 WO2000006190A1 (en) | 1998-07-30 | 1999-07-29 | THYMOSIN β4 PROMOTES WOUND REPAIR |
Country Status (12)
Country | Link |
---|---|
US (6) | US20070111931A9 (en) |
EP (3) | EP2311485A1 (en) |
AT (1) | ATE292473T1 (en) |
AU (1) | AU766826B2 (en) |
CA (1) | CA2338928A1 (en) |
DE (1) | DE69924615T3 (en) |
DK (1) | DK1100529T4 (en) |
ES (1) | ES2239846T5 (en) |
HK (1) | HK1038307A1 (en) |
MX (1) | MXPA01001041A (en) |
PT (1) | PT1100529E (en) |
WO (1) | WO2000006190A1 (en) |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10030149A1 (en) * | 2000-06-20 | 2002-01-10 | Switch Biotech Ag | Use of novel polypeptide or its variant or nucleic acid encoding the polypeptide for diagnosing and/or preventing and/or treating skin disorders and/or treatment in wound healing or for identifying active substances |
FR2814076A1 (en) * | 2000-09-21 | 2002-03-22 | Centre Nat Rech Scient | Use of tetrapeptides to promote angiogenesis in treatment of ischemias, lesions, ulcers, and the like and as angiogenesis additives in tissue culture |
WO2002030979A2 (en) * | 1999-10-15 | 2002-04-18 | Curagen Corporation | Polypeptides homologous to thymosin, ephrin a receptors, and fibromodulin, and polynucleotides encoding same |
WO2002036143A1 (en) | 2000-11-02 | 2002-05-10 | Regenerx Biopharmaceuticals, Inc. | Inhibition or reversal of skin aging by actin-sequestering peptides |
WO2002074193A2 (en) * | 2001-03-15 | 2002-09-26 | Regenerx, Biopharmaceuticals, Inc. | METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES |
WO2003020215A2 (en) | 2001-08-29 | 2003-03-13 | Regenerx Biopharmaceuticals, Inc. | Methods of treating mycocardial event related coditions with thymosin beta 4 |
US6586185B2 (en) | 2000-06-20 | 2003-07-01 | Switch Biotech Ag | Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances |
EP1369107A1 (en) * | 2002-06-03 | 2003-12-10 | Jan Marini Skin Research Inc. | Cosmetic skin care compositions |
EP1404268A1 (en) * | 2001-05-17 | 2004-04-07 | Regenerx Biopharmaceuticals, Inc. | Treating epidermlyosis bullosa with thymosin beta 4 |
EP1499339A1 (en) * | 2002-04-12 | 2005-01-26 | Yale University | Anti-inflammatory and wound healing effects of lymphoid thymosin beta 4 |
WO2005007118A2 (en) * | 2003-07-18 | 2005-01-27 | Regenerx Biopharmaceuticals, Inc. | Treatment or prevention of damage due to radiation exposure |
US6855806B1 (en) | 1999-10-15 | 2005-02-15 | Curagen Corporation | Thymosin beta 10-like proteins and nucleic acids encoding same |
WO2006076588A1 (en) * | 2005-01-13 | 2006-07-20 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease |
EP1706136A2 (en) * | 2003-12-22 | 2006-10-04 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
EP1720904A1 (en) * | 2004-03-05 | 2006-11-15 | Regenerx, Biopharmaceuticals, Inc. | Treating or preventing extracellular matrix build-up |
EP1784204A2 (en) * | 2004-08-20 | 2007-05-16 | The University of Texas Southwestern Medical Centre at Dallas | Method of treating, preventing, inhibiting or reducing damage to cardiac tissue |
WO2008024195A2 (en) * | 2006-08-18 | 2008-02-28 | Regenerx Biopharmaceuticals, Inc. | Methods and compositions for conserving and/or preparing an organ or tissue for transplant |
EP1896050A2 (en) * | 2005-06-17 | 2008-03-12 | Regenerx Biopharmaceuticals, Inc. | Lkktet and/or lkktnt peptide compositions and methods |
WO2008045345A3 (en) * | 2006-10-06 | 2008-06-26 | Regenerx Biopharmaceuticals | Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating nf-kappab or suppressing nf-kappab-mediated actions |
AU2006233251B2 (en) * | 2001-03-15 | 2008-10-02 | Regenerx Biopharmaceuticals, Inc. | Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives |
JP2009502938A (en) * | 2005-07-26 | 2009-01-29 | リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド | How to treat or prevent tissue deterioration, damage, or breakage caused by congestive heart failure |
US7531318B2 (en) | 2004-08-20 | 2009-05-12 | Board Of Regents, The University Of Texas System | Screening of agents for activity against ischemic myocardial insults |
EP2075012A1 (en) | 2001-12-21 | 2009-07-01 | PSIMEDICA Limited | Medical fibres |
US7563766B2 (en) * | 2002-01-25 | 2009-07-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the promotion of a hair growth utilizing actin binding peptides |
AU2008201749B2 (en) * | 2002-02-06 | 2010-05-13 | Regenerx Biopharmaceuticals, Inc. | Treatment of Infections and Other Disorders |
US7816321B2 (en) * | 2005-07-15 | 2010-10-19 | Beijing Northland Biotech. Co., Ltd. | Thymosin β4 derivatives and use thereof |
CN101297965B (en) * | 2008-06-16 | 2011-01-05 | 浙江省中医药研究院 | Applications of thymic peptide beta4 in preparing medicament for preventing and treating bronchial asthma |
US20110144020A1 (en) * | 2002-02-06 | 2011-06-16 | Regenerx Biopharmaceuticals, Inc. | Treatment of infections and other disorders |
US8143218B2 (en) | 1998-07-30 | 2012-03-27 | Regenerx Biopharmaceuticals, Inc. | Treatment of skin, and wound repair, with thymosin beta 4 |
EP2498794A1 (en) * | 2009-11-10 | 2012-09-19 | Adistem Ltd | Method of treatment of type 2 diabetes |
WO2012126047A1 (en) * | 2011-03-18 | 2012-09-27 | Adistem Ltd | Agent and method for treating pain and reducing inflammation |
US20130085108A1 (en) * | 2010-03-26 | 2013-04-04 | Samsungn Life Welfare Foundation | Peptides for promoting angiogenesis and an use thereof |
WO2013096773A2 (en) * | 2011-12-23 | 2013-06-27 | Henry Ford Health System | Methods, systems, and compositions for promoting recovery of peripheral neuropathy |
US9035037B2 (en) | 2007-12-21 | 2015-05-19 | Coda Therapeutics, Inc. | Medical devices |
US9808654B2 (en) | 2013-02-11 | 2017-11-07 | Jan Marini Skin Research | Post procedure skin care gel and methods of use thereof |
EP3242677A4 (en) * | 2015-01-06 | 2018-09-26 | CardioVascular BioTherapeutics, Inc. | Therapeutic angiogenesis for wound healing |
US10433783B2 (en) | 2015-02-16 | 2019-10-08 | Cardiovascular Biotherapeutics, Inc. | Therapeutic angiogenesis for treating erectile conditions |
CN110585055A (en) * | 2019-08-26 | 2019-12-20 | 武汉贝缇安卡医疗健康投资有限公司 | Application of AcSDKP in increasing content of III type collagen secreted by fibroblast |
US10966610B2 (en) | 2015-01-06 | 2021-04-06 | Venturis Therapeutics, Inc. | Angiogenic treatment of ischemic heart disease |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070191275A1 (en) * | 1998-07-30 | 2007-08-16 | Regenerx Biopharmaceuticals, Inc. | Method of treating, preventing, inhibiting or reducing damage to cardiac tissue with thymosin beta 4 fragments |
US20070015698A1 (en) * | 1998-07-30 | 2007-01-18 | United States Of America As Represented By The Secretary Of Health | Treatment of skin, and wound repair, with thymosin beta 4 |
US20080096817A1 (en) * | 1998-07-30 | 2008-04-24 | Regenerx Biopharmaceuticals, Inc. | METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES |
US20040170625A1 (en) * | 1998-07-30 | 2004-09-02 | Regenerx Biopharmaceuticals, Inc. | Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivatives |
US8652546B2 (en) | 2007-09-06 | 2014-02-18 | Tahitian Noni International, Inc. | Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals |
US7244463B2 (en) * | 2005-10-18 | 2007-07-17 | Tahitian Noni International, Inc. | Garcinia mangostana L. enhanced animal food product |
US20110217394A1 (en) * | 2000-12-05 | 2011-09-08 | Brett Justin West | Iridoid Based Formulations |
US6855345B2 (en) * | 2001-11-02 | 2005-02-15 | Morinda, Inc. | Preventative and treatment effects of Morinda citrifolia on diabetes and its related conditions |
US20040192761A1 (en) * | 2003-03-25 | 2004-09-30 | Palu Afa Kehaati | Preventative and treatment effects of morinda citrifolia as an aromatase inhibitor |
US8790727B2 (en) * | 2000-12-05 | 2014-07-29 | Tahitian Noni International, Inc. | Morinda citrifolia and iridoid based formulations |
US20070196527A1 (en) * | 2006-02-23 | 2007-08-23 | Jensen Claude J | Preventative and treatment effects of Morinda citrifolia on Osteoarthritis and its related conditions |
US8574642B2 (en) | 2000-12-05 | 2013-11-05 | Tahitian Noni International, Inc. | Antiviral Morinda citrifolia L. based formulations and methods of administration |
US20110171333A1 (en) * | 2000-12-05 | 2011-07-14 | Bryant Wadsworth | Morinda Citrifolia Based Antioxidant and Antimicrobial Formulations for Improved Color Stability and Increased Shelf Life of Various Meat Products |
WO2002083159A1 (en) * | 2001-04-17 | 2002-10-24 | Morinda, Inc. | Palliative effects of morinda citrifolia oil and juice |
US7070813B2 (en) * | 2001-11-02 | 2006-07-04 | Morinda, Inc. | Preventative and treatment effects of morinda citrifolia as a colon cancer cell growth inhibitor |
US7442395B2 (en) * | 2002-11-14 | 2008-10-28 | Tahitian Noni International, Inc. | Formulation for treating candidiasis using Morinda citrifolia |
US20110160057A1 (en) * | 2001-11-14 | 2011-06-30 | Bryant Wadsworth | Morinda Citrifolia Based Antimicrobial Formulations |
US7202066B2 (en) * | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
EP1613369A4 (en) * | 2003-03-31 | 2008-10-01 | Regenerx Biopharmaceuticals | Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives |
US20060269630A1 (en) * | 2003-04-16 | 2006-11-30 | Palu Afa K | Morinda citrifolia as a 5-Lipoxygenase inhibitor |
JP4073826B2 (en) * | 2003-06-04 | 2008-04-09 | タヒチアン ノニ インターナショナル インコーポレーテッド | Agricultural vital agent containing extract of Yaeyama Aoki |
US20070259060A1 (en) * | 2003-08-12 | 2007-11-08 | Mian-Ying Wang | Formulations and Methods for Treating Breast Cancer with Morinda Citrifolia and Methylsulfonymethane |
US20060204601A1 (en) * | 2005-03-09 | 2006-09-14 | Palu Afa K | Formulations and methods for preventing and treating substance abuse and addiction |
US20060280818A1 (en) * | 2005-05-26 | 2006-12-14 | Palu Afa K | Nicotinic acetylcholine receptor antagonist |
US20070122507A1 (en) * | 2005-05-26 | 2007-05-31 | Palu Afa K | Histone deacetylase and tumor necrosis factor converting enzyme inhibition |
US20070184137A1 (en) * | 2005-11-29 | 2007-08-09 | Palu Afa K | Morinda Citrifolia L. Based Formulations for Inhibiting Matrix Metalloproteinase Enzymes |
US20070154579A1 (en) * | 2005-11-29 | 2007-07-05 | Palu Afa K | Morinda Citrifolia Based Formulation And Methods For Weight Management |
US20070166417A1 (en) * | 2005-11-29 | 2007-07-19 | Palu Afa K | Formulation and Methods for Use of Morinda Citrifolia Seed Oil |
WO2007070660A2 (en) | 2005-12-13 | 2007-06-21 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
JP2009523804A (en) * | 2006-01-17 | 2009-06-25 | リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド | Methods for treating or preventing tissue damage caused by increased blood flow |
US20070281903A1 (en) * | 2006-05-04 | 2007-12-06 | Palu Afa K | Morinda Citrifolia-Based Formulation 5-LOX And 15-LOX |
US8025910B2 (en) | 2006-05-12 | 2011-09-27 | Tahitian Noni International, Inc. | Method and composition for administering bioactive compounds derived from Morinda citrifolia |
US8535741B2 (en) | 2006-05-12 | 2013-09-17 | Morinda, Inc. | Method and composition for administering bioactive compounds derived from Morinda citrifolia |
KR20150072458A (en) | 2006-11-15 | 2015-06-29 | 코다 테라퓨틱스, 인크. | Improved methods and compositions for wound healing |
CA2621452A1 (en) * | 2007-02-21 | 2008-08-21 | Innovational Holdings, Llc | Stent and method for reducing tissue damage after ischemic injury with thymosin b4 |
US20080317890A1 (en) * | 2007-06-21 | 2008-12-25 | Claude Jarakae Jensen | Method for treating visual impairment through the prophylactic administration of a morinda citrifolia-based naturaceutical |
US9770535B2 (en) * | 2007-06-21 | 2017-09-26 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
CA2699026A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009033816A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent |
KR20100057050A (en) * | 2007-09-11 | 2010-05-28 | 몬도바이오테크 래보래토리즈 아게 | Use of a deslorelin and mastoparan as a therapeutic agent |
US20090196944A1 (en) * | 2008-02-01 | 2009-08-06 | Brad Rawson | Methods of Manufacture of Morinda Citrifolia Based Compositions for Treatment of Anti-Inflammatory Diseases through Inhibition of Cox-1, Cox-2, Interleukin -1beta, Interleukin-6, TNF-alpha, HLE, and iNOS |
CN102006891B (en) | 2008-02-13 | 2017-04-26 | 哈佛学院董事会 | Continuous cell programming devices |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
US9012399B2 (en) | 2008-05-30 | 2015-04-21 | President And Fellows Of Harvard College | Controlled release of growth factors and signaling molecules for promoting angiogenesis |
US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
JP2012522005A (en) * | 2009-03-26 | 2012-09-20 | ヘンリー フォード ヘルス システム | Methods to improve neurological outcome after nerve injury and neurodegenerative diseases |
WO2010120749A2 (en) | 2009-04-13 | 2010-10-21 | President And Fellow Of Harvard College | Harnessing cell dynamics to engineer materials |
US8230654B2 (en) | 2009-06-10 | 2012-07-31 | Comc, Llc | Medallion insert for modular flooring assemblies |
US8782989B2 (en) | 2009-06-11 | 2014-07-22 | Comc, Llc | Narrow lined modular flooring assemblies |
JP5926180B2 (en) | 2009-07-31 | 2016-05-25 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Methods of cell programming for tolerogenic therapy |
US20110206786A1 (en) * | 2010-02-23 | 2011-08-25 | Brett Justin West | Acai and Iridoid Based Formulations |
EP2542230A4 (en) | 2010-03-05 | 2013-08-28 | Harvard College | Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1 |
EP2585053A4 (en) | 2010-06-25 | 2014-02-26 | Harvard College | Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones |
WO2012044783A2 (en) * | 2010-09-30 | 2012-04-05 | Regenerx Biopharmaceuticals, Inc. | Method of achieving a thymosin beta 4 concentration in a human patient |
PT2624873T (en) | 2010-10-06 | 2020-03-04 | Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
WO2012064697A2 (en) | 2010-11-08 | 2012-05-18 | President And Fellows Of Harvard College | Materials presenting notch signaling molecules to control cell behavior |
WO2012148684A1 (en) | 2011-04-27 | 2012-11-01 | President And Fellows Of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
ES2878089T3 (en) | 2011-04-28 | 2021-11-18 | Harvard College | Injectable preformed macroscopic three-dimensional scaffolds for minimally invasive administration |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
EP2714073B1 (en) | 2011-06-03 | 2021-03-10 | President and Fellows of Harvard College | In situ antigen-generating cancer vaccine |
US20130022687A1 (en) * | 2011-07-19 | 2013-01-24 | Fitzgerald Jr John James | Topical transdermal method for delivering nutrients through the skin for expedited wound healing |
US8632827B2 (en) * | 2011-12-13 | 2014-01-21 | Avon Products, Inc | Modulation of thymosin beta-4 in skin |
ES2773895T3 (en) | 2012-04-16 | 2020-07-15 | Harvard College | Mesoporous Silica Compositions to Modulate Immune Responses |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
DE102013017203A1 (en) * | 2013-10-16 | 2015-04-16 | Isa Atay | thymus |
EP3137105A4 (en) | 2014-04-30 | 2017-12-27 | President and Fellows of Harvard College | Combination vaccine devices and methods of killing cancer cells |
EA201790434A1 (en) | 2014-08-22 | 2017-07-31 | Окленд Юнисервисиз Лимитед | CHANNEL MODULATORS |
KR101530278B1 (en) * | 2014-09-04 | 2015-06-24 | 부산대학교 산학협력단 | Pharmaceutical Compositon for ischemic heart diseases Comprising AAV including Cardiomyocytes Converson Factors and Cardiovascular Regenerative Gene |
BR112017005631A2 (en) | 2014-09-19 | 2018-06-26 | City Of Hope | il13ra2-targeted chimeric costimulator antigen receptor t cells |
EP3210614A4 (en) * | 2014-10-22 | 2018-06-13 | G-Treebnt Co., Ltd. | Composition containing thymosin beta 4, and pharmaceutical formulation comprising same |
EP3250250A4 (en) | 2015-01-30 | 2019-05-22 | President and Fellows of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
CN107708756A (en) | 2015-04-10 | 2018-02-16 | 哈佛学院院长等 | Immunocyte acquisition equipment and its preparation and application |
CN108026729B (en) | 2015-09-10 | 2020-02-14 | Comc有限责任公司 | Modular flooring assembly |
US10744088B2 (en) | 2015-10-06 | 2020-08-18 | G-Treebnt Co., Ltd. | Method for preparing ophthalmic preparation containing thymosin beta-4 |
EP3411475A4 (en) | 2016-02-06 | 2019-09-11 | President and Fellows of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
MX2018013546A (en) * | 2016-05-06 | 2019-04-22 | Phasebio Pharmaceuticals Inc | Elp fusion proteins for controlled and sustained release. |
AU2017295704B2 (en) | 2016-07-13 | 2023-07-13 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
KR102340750B1 (en) * | 2017-03-03 | 2021-12-21 | 에이치엘비테라퓨틱스 주식회사 | Stabilized topical composition comprising thymosin beta 4 as an active ingredient |
CN111249534B (en) * | 2020-01-16 | 2021-06-15 | 中国人民解放军总医院 | Bioactive scaffold capable of promoting synchronous repair and regeneration of wound tissues and preparation method thereof |
EP4132546A4 (en) * | 2020-04-07 | 2024-05-01 | Combangio Inc | Lyophilized mesenchymal stem cell derived secretome and uses thereof |
CN111888462B (en) * | 2020-08-10 | 2022-08-26 | 中国人民解放军军事科学院军事医学研究院 | Application of thymosin beta 4 in preparation of microecological balance regulator |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0124779A2 (en) * | 1983-04-07 | 1984-11-14 | The George Washington University | Radioimmunological assay of thymosin-beta 4 |
WO1994011499A1 (en) * | 1992-11-13 | 1994-05-26 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Flk-1 is a receptor for vascular endothelial growth factor |
WO1996016983A1 (en) * | 1994-11-30 | 1996-06-06 | La Jolla Cancer Research Foundation | Cooperative combinations of ligands contained within a matrix |
WO1997048805A1 (en) * | 1996-06-17 | 1997-12-24 | Children's Medical Center Corporation | HUMAN THYMOSIN β15 GENE, PROTEIN AND USES THEREOF |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4261982A (en) * | 1977-11-09 | 1981-04-14 | The Procter & Gamble Company | Therapeutic composition |
US4297276A (en) * | 1979-03-23 | 1981-10-27 | Hoffman-La Roche Inc. | Thymosin beta 3 and beta 4 |
US4444757A (en) * | 1981-11-16 | 1984-04-24 | Research Corporation | Use of thymosin as an anti-diabetes and anti-hypertensive disease agent |
US4389343A (en) * | 1981-12-24 | 1983-06-21 | Hoffmann-La Roche Inc. | Immunopotentiating peptides from thymus |
US4388234A (en) * | 1981-12-28 | 1983-06-14 | Hoffmann-La Roche Inc. | Peptide isolation |
FR2530466A1 (en) | 1982-07-21 | 1984-01-27 | Hecmati Michel | Anti-wrinkle gel, product and process |
WO1984002274A1 (en) | 1982-12-09 | 1984-06-21 | Hafsten Raymond J Jr | Activated, stabilized enzymes useful for wound healing |
WO1984003437A1 (en) | 1983-03-01 | 1984-09-13 | Rudolf Trensch | Method and product for the treatment or hair |
GB8330969D0 (en) * | 1983-11-21 | 1983-12-29 | Wellcome Found | Promoting healing |
JPS60142908A (en) | 1983-12-29 | 1985-07-29 | Kanebo Ltd | Hair tonic cosmetic |
GB8517402D0 (en) * | 1985-07-10 | 1985-08-14 | Wellcome Found | Treatment of viral infections |
US4713394A (en) * | 1986-01-17 | 1987-12-15 | Thornfeldt Carl R | Treatment of nonacne inflammatory and infectious dermatoses and hair loss |
JPS62252711A (en) | 1986-04-24 | 1987-11-04 | Hideharu Tamaki | Hair tonic |
US4983581A (en) * | 1988-05-20 | 1991-01-08 | Institute Of Molecular Biology, Inc. | Wound healing composition of IGF-I and TGF-β |
US5055447A (en) * | 1988-07-28 | 1991-10-08 | Genentech, Inc. | Method and compositions for the treatment and prevention of septic shock |
JPH02101019A (en) * | 1988-10-05 | 1990-04-12 | Genichiro Soma | Anti-aids agent |
JPH02142717A (en) | 1988-11-22 | 1990-05-31 | Kanebo Ltd | Hair nouring cosmetic |
EP0410348A1 (en) | 1989-07-26 | 1991-01-30 | G.D. Searle & Co. | Topical spironolactone composition |
US5068315A (en) | 1990-04-12 | 1991-11-26 | University Of Dundee | Composition for the regulation of hair growth |
GB9014221D0 (en) | 1990-06-26 | 1990-08-15 | Janssen Pharmaceutica Nv | Method of treating alopecia |
JPH04234325A (en) * | 1990-12-27 | 1992-08-24 | Hoechst Japan Ltd | Treating and preventive medicine for brain and nerve disorder |
US6124259A (en) * | 1993-01-28 | 2000-09-26 | Celtrix Pharmaceuticals, Inc. | Method for treating ophthalmic disorders with IGFBP |
AU6204594A (en) * | 1993-02-22 | 1994-09-14 | Ulrich-Christoph Von Arnim | Use of heparins for the treatment of inflammatory or immunological diseases |
AU6771594A (en) * | 1993-04-22 | 1994-11-08 | George Washington University, The | Method of decreasing the toxicity of therapeutic compositions using thymosin beta 4 |
US5358703A (en) * | 1993-09-27 | 1994-10-25 | Mcw Research Foundation, Inc. | Method for the detection of nitric oxide |
US5593964A (en) * | 1993-10-07 | 1997-01-14 | The George Washington University Medical Center | Method of treating septic shock by preventing actin polymerization |
WO1995009646A1 (en) * | 1993-10-07 | 1995-04-13 | The George Washington University Medical Center | METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN β¿4? |
US5578570A (en) * | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
FR2711060B1 (en) * | 1993-10-13 | 1995-11-17 | Oreal | Method for modifying the growth of hair and / or hair and compositions which can be used for this purpose. |
US5591716A (en) * | 1993-11-19 | 1997-01-07 | New York University | Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins |
CA2139385C (en) * | 1994-02-04 | 2001-12-25 | Gottfried Alber | Products containing g-csf and tnf binding protein |
US5652209A (en) * | 1994-04-29 | 1997-07-29 | University Of Miami | Use of secretory products of human lacrimal gland acinar epithelia for tear replacement therapy |
FR2719481B1 (en) | 1994-05-05 | 1996-05-31 | Oreal | Composition based on antifungal compounds and halogenated antibacterial compounds to reduce hair loss. |
JPH07316022A (en) | 1994-05-24 | 1995-12-05 | Kyowa Hakko Kogyo Co Ltd | Hair tonic |
JP3202135B2 (en) | 1994-08-10 | 2001-08-27 | カネボウ株式会社 | Hair cosmetics |
DE19509354A1 (en) * | 1994-12-08 | 1996-06-13 | Klett Loch Lore M | Combination preparation for promoting hair growth and possibly skin and nail growth and for preventing or eliminating hair loss |
FR2741076B1 (en) | 1995-11-15 | 1998-01-30 | Rech De Pathologie Appliquee S | PEPTIDE CONJUGATES DERIVED FROM THERMAL HORMONES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THEM |
DE19622422A1 (en) * | 1996-06-04 | 1997-12-11 | Sanorell Pharma Gmbh & Co | Storage-stable pharmaceutical composition with immunomodulating and anti-inflammatory properties and a process for its production |
JP3128203B2 (en) * | 1997-02-10 | 2001-01-29 | 一男 坪田 | Inhibitor of adhesion between secretory gland cells and lymphocytes |
DE19711939A1 (en) * | 1997-03-21 | 1998-09-24 | Bosch Gmbh Robert | Device for detecting the pressure and the temperature in the intake manifold of an internal combustion engine |
DE19731420A1 (en) * | 1997-07-22 | 1999-01-28 | Bosch Gmbh Robert | Device for detecting the pressure and temperature in the intake manifold of an internal combustion engine and method for its production |
US6030948A (en) * | 1997-12-19 | 2000-02-29 | Mann; Morris A. | Hair regeneration compositions for treatment of alopecia and methods of application related thereto |
GB9806632D0 (en) | 1998-03-28 | 1998-05-27 | Stevenson Robert | Peptide factor |
US20040067227A1 (en) * | 2001-11-02 | 2004-04-08 | Goldstein Allan L. | Inhibition or reversal of skin aging by actin-sequestering peptides |
WO2002036143A1 (en) | 2000-11-02 | 2002-05-10 | Regenerx Biopharmaceuticals, Inc. | Inhibition or reversal of skin aging by actin-sequestering peptides |
CA2338928A1 (en) | 1998-07-30 | 2000-02-10 | Hynda K. Kleinman | Thymosin .beta.4 promotes wound repair |
US6586403B1 (en) * | 2000-07-20 | 2003-07-01 | Salpep Biotechnology, Inc. | Treating allergic reactions and inflammatory responses with tri-and dipeptides |
US7560280B2 (en) * | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
US6821524B2 (en) * | 2002-06-03 | 2004-11-23 | Jan Marini Skin Research, Inc. | Cosmetic skin care compositions |
JP3870918B2 (en) * | 2002-10-23 | 2007-01-24 | 株式会社デンソー | Temperature sensor integrated pressure sensor device |
RU2295963C1 (en) | 2005-10-18 | 2007-03-27 | Закрытое акционерное общество Научно-производственное предприятие "Тринита" | Method for producing immunostimulator |
-
1999
- 1999-07-29 CA CA002338928A patent/CA2338928A1/en not_active Abandoned
- 1999-07-29 EP EP10186120A patent/EP2311485A1/en not_active Withdrawn
- 1999-07-29 ES ES99937654T patent/ES2239846T5/en not_active Expired - Lifetime
- 1999-07-29 EP EP04078459A patent/EP1591128A1/en not_active Withdrawn
- 1999-07-29 WO PCT/US1999/017282 patent/WO2000006190A1/en active IP Right Grant
- 1999-07-29 MX MXPA01001041A patent/MXPA01001041A/en active IP Right Grant
- 1999-07-29 EP EP99937654A patent/EP1100529B2/en not_active Expired - Lifetime
- 1999-07-29 DE DE69924615T patent/DE69924615T3/en not_active Expired - Lifetime
- 1999-07-29 PT PT99937654T patent/PT1100529E/en unknown
- 1999-07-29 DK DK99937654.4T patent/DK1100529T4/en active
- 1999-07-29 AT AT99937654T patent/ATE292473T1/en active
- 1999-07-29 AU AU52443/99A patent/AU766826B2/en not_active Ceased
-
2001
- 2001-01-29 US US09/772,445 patent/US20070111931A9/en not_active Abandoned
- 2001-11-23 HK HK01108257A patent/HK1038307A1/en not_active IP Right Cessation
-
2004
- 2004-05-26 US US10/853,505 patent/US7268118B2/en not_active Expired - Fee Related
-
2005
- 2005-11-22 US US11/284,430 patent/US8143218B2/en not_active Expired - Fee Related
-
2007
- 2007-03-09 US US11/715,997 patent/US20090023663A1/en not_active Abandoned
-
2010
- 2010-11-02 US US12/938,228 patent/US20110124550A1/en not_active Abandoned
-
2017
- 2017-05-12 US US15/594,045 patent/US20170326207A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0124779A2 (en) * | 1983-04-07 | 1984-11-14 | The George Washington University | Radioimmunological assay of thymosin-beta 4 |
WO1994011499A1 (en) * | 1992-11-13 | 1994-05-26 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Flk-1 is a receptor for vascular endothelial growth factor |
WO1996016983A1 (en) * | 1994-11-30 | 1996-06-06 | La Jolla Cancer Research Foundation | Cooperative combinations of ligands contained within a matrix |
WO1997048805A1 (en) * | 1996-06-17 | 1997-12-24 | Children's Medical Center Corporation | HUMAN THYMOSIN β15 GENE, PROTEIN AND USES THEREOF |
Non-Patent Citations (22)
Title |
---|
CECH, J.AMER.MED. ASSN., vol. 260, 1988, pages 3030 |
DE MESMAEKER ET AL.: "Backbone modifications in oligonucleotides and peptide nucleic acid systems", CURR. OPIN. STRUCT. BIOL, vol. 5, 1995, pages 343 - 355 |
FRANK, S ET AL: "Regulation of vascular endothelial growth factor expression in cultured keratinocytes and implications for normal and impaired wound healing", J. BIOL. CHEM., vol. 270, no. 21, May 1995 (1995-05-01), pages 12607 - 12613, XP002125696 * |
GEWIRTZ, A.M. ET AL.: "Facilitating delivery of antisense oligodeoxynucleotides: Helping antisense deliver on its promise", PROC. NATL. ACAD SCI. U.S.A., vol. 93, 1996, pages 3161 - 3163 |
GOEY ET AL., J. LMMUNOL., vol. 143, 1989, pages 877 - 880 |
GROTENDORST, GR ET AL., J. CLIN. INVEST., vol. 76, 1985, pages 2323 - 2329 |
HANNAPPEL E & WARTENBERG F: "Actin-sequestring ability of thymosin beta 4, thymosin beta 4 fragments and thymosin beta 4-like peptides as assessed by the DNAse I inhibition assay", BIOL. CHEM., vol. 374, February 1993 (1993-02-01), pages 117 - 122, XP002118663 * |
HASSELHOFF, NATURE, vol. 334, 1988, pages 585 |
IGNOTZ ET AL., J. BIOL CHEM., vol. 261, 1986, pages 4337 - 4345 |
KOHLER N. ET AL., EXP. CELL RES., vol. 87, 1974, pages 297 - 301 |
MALINDA K M ET AL: "Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells.", FASEB JOURNAL, vol. 11, no. 6, May 1997 (1997-05-01), pages 474 - 481, XP002125695 * |
MANNINO ET AL., BIOTECHNIQUES, vol. 6, 1988, pages 682 |
MUSTOE ET AL., SCIENCE, vol. 237, 1987, pages 1333 - 1335 |
NIMNI M E: "Polypeptide growth factors: targeted delivery systems", BIOMATERIALS, vol. 18, no. 18, 1997, pages 1201 - 1225, XP004086390, ISSN: 0142-9612 * |
NODA ET AL., ENDOCRINOLOGY, vol. 124, 1989, pages 2991 - 2995 |
PIERCE, GF ET AL., J. EXP. MED., vol. 167, 1988, pages 974 - 987 |
PIETENPOL ET AL., PROC. NAT'L. ACAD SCI. USA, vol. 87, 1990, pages 3758 - 3762 |
ROSS R. ET AL., PROC NAT'Ì ACAD SCI USA, vol. 71, no. 4, pages 1207 - 1210 |
SABOLINSKI M L ET AL: "Cultured skin as a 'smart material' for healing wounds: experience in venous ulcers", BIOMATERIALS, vol. 17, no. 3, 1996, pages 311 - 320, XP004032797, ISSN: 0142-9612 * |
SPORN, MB ET AL., SCIENCE, vol. 219, 1983, pages 1329 |
STEIN, C.A.: "A discussion of G-tetrads 1996. Exploiting the potential of antisense: beyond phosphorothioate oligodeoxynucleotides", CHEM. AND BIOL., vol. 3, pages 319 - 323 |
SUN H -Q ET AL: "BETA-THYMOSINS ARE NOT SIMPLE ACTIN MONOMER BUFFERING PROTEINS. INSIGHTS FROM OVEREXPRESSION STUDIES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 16, April 1996 (1996-04-01), pages 9223 - 9230, XP002041936, ISSN: 0021-9258 * |
Cited By (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8143218B2 (en) | 1998-07-30 | 2012-03-27 | Regenerx Biopharmaceuticals, Inc. | Treatment of skin, and wound repair, with thymosin beta 4 |
WO2002030979A3 (en) * | 1999-10-15 | 2003-06-19 | Curagen Corp | Polypeptides homologous to thymosin, ephrin a receptors, and fibromodulin, and polynucleotides encoding same |
US6992170B2 (en) | 1999-10-15 | 2006-01-31 | Curagen Corporation | Polypeptides and polynucleotides homologous to thymosin, ephrin a receptors, and fibromodulin |
WO2002030979A2 (en) * | 1999-10-15 | 2002-04-18 | Curagen Corporation | Polypeptides homologous to thymosin, ephrin a receptors, and fibromodulin, and polynucleotides encoding same |
US6855806B1 (en) | 1999-10-15 | 2005-02-15 | Curagen Corporation | Thymosin beta 10-like proteins and nucleic acids encoding same |
DE10030149A1 (en) * | 2000-06-20 | 2002-01-10 | Switch Biotech Ag | Use of novel polypeptide or its variant or nucleic acid encoding the polypeptide for diagnosing and/or preventing and/or treating skin disorders and/or treatment in wound healing or for identifying active substances |
US6586185B2 (en) | 2000-06-20 | 2003-07-01 | Switch Biotech Ag | Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances |
US7235532B2 (en) | 2000-09-21 | 2007-06-26 | Centre National De La Recherche Scientfique | Angiogenic agents and their uses |
WO2002024218A1 (en) * | 2000-09-21 | 2002-03-28 | Centre National De La Recherche Scientifique (Cnrs) | Angiogenic agents and their uses |
JP2004509148A (en) * | 2000-09-21 | 2004-03-25 | サントル ナシオナル ドゥ ラ ルシェルシュ シアンティフィーク(セーエヌエールエス) | Angiogenic agent and use thereof |
JP4925551B2 (en) * | 2000-09-21 | 2012-04-25 | サントル・ナシオナル・ドウ・ラ・ルシエルシユ・シアンテイフイク(セー・エヌ・エール・エス) | Angiogenic agents and uses thereof |
FR2814076A1 (en) * | 2000-09-21 | 2002-03-22 | Centre Nat Rech Scient | Use of tetrapeptides to promote angiogenesis in treatment of ischemias, lesions, ulcers, and the like and as angiogenesis additives in tissue culture |
JP2009046502A (en) * | 2000-11-02 | 2009-03-05 | Regenerx Biopharmaceuticals Inc | Use of skin degeneration disruption polypeptide containing amino acid sequence lkktet for producing composition promoting skin condition improvement |
WO2002036143A1 (en) | 2000-11-02 | 2002-05-10 | Regenerx Biopharmaceuticals, Inc. | Inhibition or reversal of skin aging by actin-sequestering peptides |
AU2002213513B2 (en) * | 2000-11-02 | 2006-05-25 | Regenerx Biopharmaceuticals, Inc. | Inhibition or reversal of skin aging by actin-sequestering peptides |
WO2002074193A3 (en) * | 2001-03-15 | 2003-12-04 | Regenerx Biopharmaceuticals | METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES |
WO2002074193A2 (en) * | 2001-03-15 | 2002-09-26 | Regenerx, Biopharmaceuticals, Inc. | METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES |
AU2006233251B2 (en) * | 2001-03-15 | 2008-10-02 | Regenerx Biopharmaceuticals, Inc. | Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives |
CN100360174C (en) * | 2001-03-15 | 2008-01-09 | 雷金纳克斯生物制药公司 | Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (t beta 4), analogues, isoforms and other derivatives |
EP1404268A4 (en) * | 2001-05-17 | 2006-03-01 | Regenerx Biopharmaceuticals | Treating epidermlyosis bullosa with thymosin beta 4 |
EP1404268A1 (en) * | 2001-05-17 | 2004-04-07 | Regenerx Biopharmaceuticals, Inc. | Treating epidermlyosis bullosa with thymosin beta 4 |
JP2009221211A (en) * | 2001-08-29 | 2009-10-01 | Regenerx Biopharmaceuticals Inc | USE OF THYMOSIN beta4, ANALOGUE, ISOFORM AND OTHER DERIVATIVE |
WO2003020215A2 (en) | 2001-08-29 | 2003-03-13 | Regenerx Biopharmaceuticals, Inc. | Methods of treating mycocardial event related coditions with thymosin beta 4 |
EP1427432A2 (en) * | 2001-08-29 | 2004-06-16 | Regenerx, Biopharmaceuticals, Inc. | Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives |
US9056087B2 (en) | 2001-08-29 | 2015-06-16 | Regenerx Biopharmaceuticals, Inc. | Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives |
EP1427432A4 (en) * | 2001-08-29 | 2008-01-23 | Regenerx Biopharmaceuticals | Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives |
EP2075012A1 (en) | 2001-12-21 | 2009-07-01 | PSIMEDICA Limited | Medical fibres |
US7563766B2 (en) * | 2002-01-25 | 2009-07-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the promotion of a hair growth utilizing actin binding peptides |
AU2008201749B2 (en) * | 2002-02-06 | 2010-05-13 | Regenerx Biopharmaceuticals, Inc. | Treatment of Infections and Other Disorders |
US20110144020A1 (en) * | 2002-02-06 | 2011-06-16 | Regenerx Biopharmaceuticals, Inc. | Treatment of infections and other disorders |
EP1499339A4 (en) * | 2002-04-12 | 2008-04-02 | Univ Yale | Anti-inflammatory and wound healing effects of lymphoid thymosin beta 4 |
EP1499339A1 (en) * | 2002-04-12 | 2005-01-26 | Yale University | Anti-inflammatory and wound healing effects of lymphoid thymosin beta 4 |
EP1369107A1 (en) * | 2002-06-03 | 2003-12-10 | Jan Marini Skin Research Inc. | Cosmetic skin care compositions |
JP2007523878A (en) * | 2003-07-18 | 2007-08-23 | リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド | Treatment or prevention of damage from radiation exposure |
WO2005007118A2 (en) * | 2003-07-18 | 2005-01-27 | Regenerx Biopharmaceuticals, Inc. | Treatment or prevention of damage due to radiation exposure |
WO2005007118A3 (en) * | 2003-07-18 | 2005-07-14 | Regenerx Biopharmaceuticals | Treatment or prevention of damage due to radiation exposure |
US20090053194A1 (en) * | 2003-12-22 | 2009-02-26 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
EP1706136A2 (en) * | 2003-12-22 | 2006-10-04 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
JP2007521336A (en) * | 2003-12-22 | 2007-08-02 | リジェナークス・バイオファーマシューティカルズ・インコーポレイテッド | Methods of treating or preventing biological or immunological responses to reactive chemicals, biological substances, or toxins |
EP1706136A4 (en) * | 2003-12-22 | 2009-09-16 | Regenerx Biopharmaceuticals | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
AU2004308378B2 (en) * | 2003-12-22 | 2010-05-13 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
US8399609B2 (en) | 2004-03-05 | 2013-03-19 | Regenerx Biopharmaceuticals, Inc. | Treating or preventing extracellular matrix build-up |
EP1720904A1 (en) * | 2004-03-05 | 2006-11-15 | Regenerx, Biopharmaceuticals, Inc. | Treating or preventing extracellular matrix build-up |
EP1720904A4 (en) * | 2004-03-05 | 2007-08-22 | Regenerx Biopharmaceuticals | Treating or preventing extracellular matrix build-up |
JP2008510732A (en) * | 2004-08-20 | 2008-04-10 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | Methods for treating, preventing, inhibiting or alleviating damage to heart tissue |
US7531318B2 (en) | 2004-08-20 | 2009-05-12 | Board Of Regents, The University Of Texas System | Screening of agents for activity against ischemic myocardial insults |
EP1784204A4 (en) * | 2004-08-20 | 2008-11-05 | Univ Texas | Method of treating, preventing, inhibiting or reducing damage to cardiac tissue |
EP1784204A2 (en) * | 2004-08-20 | 2007-05-16 | The University of Texas Southwestern Medical Centre at Dallas | Method of treating, preventing, inhibiting or reducing damage to cardiac tissue |
US8716215B2 (en) | 2005-01-13 | 2014-05-06 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease |
JP2008526986A (en) * | 2005-01-13 | 2008-07-24 | リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド | A method of treating or preventing deterioration, injury or damage of tissue due to neurodegenerative disease, muscle degenerative disease or neuromuscular degenerative disease, or method of repairing tissue adversely affected by the disease |
WO2006076588A1 (en) * | 2005-01-13 | 2006-07-20 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease |
EP1896050A2 (en) * | 2005-06-17 | 2008-03-12 | Regenerx Biopharmaceuticals, Inc. | Lkktet and/or lkktnt peptide compositions and methods |
US8383576B2 (en) | 2005-06-17 | 2013-02-26 | Regenerx Biopharmaceuticals, Inc. | LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized |
EP3326647A1 (en) * | 2005-06-17 | 2018-05-30 | Regenerx Biopharmaceuticals, Inc. | Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized |
EP1896050A4 (en) * | 2005-06-17 | 2010-01-27 | Regenerx Biopharmaceuticals | Lkktet and/or lkktnt peptide compositions and methods |
CN105106931A (en) * | 2005-06-17 | 2015-12-02 | 雷金纳克斯生物制药公司 | LKKTET and/or LKKTNT peptide compositions in lyophilized or lyophilizable mode |
US10004785B2 (en) | 2005-06-17 | 2018-06-26 | Regenerx Biopharmaceuticals, Inc. | LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized |
US9821030B2 (en) | 2005-06-17 | 2017-11-21 | Regenerx Biopharmaceuticals, Inc. | LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized |
US9585941B2 (en) | 2005-06-17 | 2017-03-07 | Regenerx Biopharmaceuticals, Inc. | Eye drop formulation |
US7816321B2 (en) * | 2005-07-15 | 2010-10-19 | Beijing Northland Biotech. Co., Ltd. | Thymosin β4 derivatives and use thereof |
US8093214B2 (en) * | 2005-07-26 | 2012-01-10 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure |
JP2009502938A (en) * | 2005-07-26 | 2009-01-29 | リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド | How to treat or prevent tissue deterioration, damage, or breakage caused by congestive heart failure |
US8426365B2 (en) | 2005-07-26 | 2013-04-23 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure |
WO2008024195A2 (en) * | 2006-08-18 | 2008-02-28 | Regenerx Biopharmaceuticals, Inc. | Methods and compositions for conserving and/or preparing an organ or tissue for transplant |
WO2008024195A3 (en) * | 2006-08-18 | 2008-07-17 | Regenerx Biopharmaceuticals | Methods and compositions for conserving and/or preparing an organ or tissue for transplant |
US20100048474A1 (en) * | 2006-10-06 | 2010-02-25 | Regenerx Biopharmaceutical, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating nf-kappabeta or supressing nf-kappabeta-mediated actions |
US8399412B2 (en) | 2006-10-06 | 2013-03-19 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions |
WO2008045345A3 (en) * | 2006-10-06 | 2008-06-26 | Regenerx Biopharmaceuticals | Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating nf-kappab or suppressing nf-kappab-mediated actions |
US10251929B2 (en) | 2007-12-21 | 2019-04-09 | Ocunexus Theraprutics, Inc. | Medical devices |
US9035037B2 (en) | 2007-12-21 | 2015-05-19 | Coda Therapeutics, Inc. | Medical devices |
US9561311B2 (en) | 2007-12-21 | 2017-02-07 | Coda Therapeutics, Inc. | Medical devices |
CN101297965B (en) * | 2008-06-16 | 2011-01-05 | 浙江省中医药研究院 | Applications of thymic peptide beta4 in preparing medicament for preventing and treating bronchial asthma |
EP2498794A1 (en) * | 2009-11-10 | 2012-09-19 | Adistem Ltd | Method of treatment of type 2 diabetes |
EP2498794A4 (en) * | 2009-11-10 | 2014-04-09 | Adistem Ltd | Method of treatment of type 2 diabetes |
US8895505B2 (en) | 2009-11-10 | 2014-11-25 | Adistem Ltd. | Method of treatment of type 2 diabetes |
US20130085108A1 (en) * | 2010-03-26 | 2013-04-04 | Samsungn Life Welfare Foundation | Peptides for promoting angiogenesis and an use thereof |
US9249185B2 (en) * | 2010-03-26 | 2016-02-02 | Industry-Academic Cooperation Foundation, Sookmyung Women's University | Peptides for promoting angiogenesis and an use thereof |
WO2012126047A1 (en) * | 2011-03-18 | 2012-09-27 | Adistem Ltd | Agent and method for treating pain and reducing inflammation |
US9775883B2 (en) | 2011-12-23 | 2017-10-03 | Henry Ford Health System | Methods, systems, and compositions for promoting recovery of peripheral neuropathy |
WO2013096773A3 (en) * | 2011-12-23 | 2013-11-21 | Henry Ford Health System | Methods, systems, and compositions for promoting recovery of peripheral neuropathy |
WO2013096773A2 (en) * | 2011-12-23 | 2013-06-27 | Henry Ford Health System | Methods, systems, and compositions for promoting recovery of peripheral neuropathy |
US9808654B2 (en) | 2013-02-11 | 2017-11-07 | Jan Marini Skin Research | Post procedure skin care gel and methods of use thereof |
EP3242677A4 (en) * | 2015-01-06 | 2018-09-26 | CardioVascular BioTherapeutics, Inc. | Therapeutic angiogenesis for wound healing |
US10966610B2 (en) | 2015-01-06 | 2021-04-06 | Venturis Therapeutics, Inc. | Angiogenic treatment of ischemic heart disease |
US10433783B2 (en) | 2015-02-16 | 2019-10-08 | Cardiovascular Biotherapeutics, Inc. | Therapeutic angiogenesis for treating erectile conditions |
CN110585055A (en) * | 2019-08-26 | 2019-12-20 | 武汉贝缇安卡医疗健康投资有限公司 | Application of AcSDKP in increasing content of III type collagen secreted by fibroblast |
Also Published As
Publication number | Publication date |
---|---|
US20070111931A9 (en) | 2007-05-17 |
DE69924615T3 (en) | 2011-05-05 |
EP1100529B1 (en) | 2005-04-06 |
MXPA01001041A (en) | 2002-06-04 |
US8143218B2 (en) | 2012-03-27 |
CA2338928A1 (en) | 2000-02-10 |
EP1100529A1 (en) | 2001-05-23 |
ES2239846T5 (en) | 2011-03-04 |
DE69924615D1 (en) | 2005-05-12 |
DK1100529T3 (en) | 2005-12-19 |
HK1038307A1 (en) | 2002-03-15 |
ES2239846T3 (en) | 2005-10-01 |
US20070009469A1 (en) | 2007-01-11 |
US20090023663A1 (en) | 2009-01-22 |
DE69924615T2 (en) | 2006-02-02 |
US20040220111A1 (en) | 2004-11-04 |
ATE292473T1 (en) | 2005-04-15 |
US20030060405A1 (en) | 2003-03-27 |
EP1100529B2 (en) | 2010-08-25 |
PT1100529E (en) | 2005-10-31 |
AU5244399A (en) | 2000-02-21 |
US20170326207A1 (en) | 2017-11-16 |
AU766826B2 (en) | 2003-10-23 |
US7268118B2 (en) | 2007-09-11 |
EP1591128A1 (en) | 2005-11-02 |
US20110124550A1 (en) | 2011-05-26 |
EP2311485A1 (en) | 2011-04-20 |
DK1100529T4 (en) | 2010-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170326207A1 (en) | Thymosin Beta 4 Promotes Wound Repair | |
US20070015698A1 (en) | Treatment of skin, and wound repair, with thymosin beta 4 | |
AU670770B2 (en) | Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix | |
Merwin et al. | Transforming growth factor beta1 modulates extracellular matrix organization and cell‐cell junctional complex formation during in vitro angiogenesis | |
CA2065860C (en) | Inhibiting transforming growth factor .beta. to prevent accumulation of extracellular matrix | |
Olerud et al. | Neutral endopeptidase expression and distribution in human skin and wounds | |
US5436228A (en) | Chemotactic wound healing peptides | |
JP2007051150A (en) | Connective tissue growth factor | |
US9056087B2 (en) | Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives | |
Minuto et al. | Evidence for autocrine mitogenic stimulation by somatomedin-C/insulin-like growth factor I on an established human lung cancer cell line | |
US6197751B1 (en) | Thymosin α1 promotes tissue repair, angiogenesis and cell migration | |
AU2002336408A1 (en) | Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives | |
US5824647A (en) | Chemotactic wound healing peptides | |
JP2009046502A (en) | Use of skin degeneration disruption polypeptide containing amino acid sequence lkktet for producing composition promoting skin condition improvement | |
WO1996036349A1 (en) | POST-TRANSLATIONAL ACTIVATION OF TGF-β1 INVOLVING THE TSP-1 RECEPTOR CD36 | |
FI81365C (en) | Process for producing biologically active polypeptides | |
AU2002213513A1 (en) | Inhibition or reversal of skin aging by actin-sequestering peptides | |
US20040067227A1 (en) | Inhibition or reversal of skin aging by actin-sequestering peptides | |
WO2004099768A1 (en) | Method for detecting development of a physiological disorder in a subject |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2338928 Country of ref document: CA Kind code of ref document: A Ref document number: 2338928 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/001041 Country of ref document: MX Ref document number: 09772445 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 52443/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999937654 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999937654 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 52443/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999937654 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 09772445 Country of ref document: US |